Bendamustine in patients with relapsed or refractory multiple myeloma (Q35958553)

11 August 2017

Bendamustine in patients with relapsed or refractory multiple myeloma (English)

1 reference

11 August 2017

1 reference

M Michael

1 reference

11 August 2017

I Bruns

1 reference

11 August 2017

E Bölke

1 reference

11 August 2017

F Zohren

1 reference

11 August 2017

A Czibere

1 reference

11 August 2017

N N Safaian

1 reference

11 August 2017

F Neumann

1 reference

11 August 2017

R Haas

1 reference

11 August 2017

G Kobbe

1 reference

11 August 2017

Roland Fenk

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

European Journal of Medical Research

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

13-19

1 reference

Validation of the self regulation questionnaire as a measure of health in quality of life research

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Validation of the brief multidimensional life satisfaction scale in patients with chronic diseases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Bendamustine: rebirth of an old drug

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Multiple myeloma: novel approaches for relapsed disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Phase I studies with bendamustine: an update

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351842

Single versus double autologous stem-cell transplantation for multiple myeloma.

2 October 2017

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Bendamustine in the treatment of multiple myeloma: results and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2047-783X-15-1-13

Standard therapy versus autologous transplantation in multiple myeloma

21 January 2018

1 reference

12 December 2020

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy

1 reference

12 December 2020

Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma

1 reference

12 December 2020

Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways

1 reference

12 December 2020

10.1186/2047-783X-15-1-13

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

20159666

1 reference